Medicenna’s Bizaxofusp Boosts Brain Cancer Survival

Medicenna Therapeutics Corp (TSE:MDNA) has released an update.

Medicenna Therapeutics Corp. has presented promising clinical data at the ASCO 2024 showing that its drug, bizaxofusp, significantly increases survival rates for patients with recurrent glioblastoma. Compared to a matched external control, bizaxofusp nearly doubled the median overall survival time and halved the risk of death. These results support bizaxofusp as a potential new standard of care that doesn’t require IL-4R expression testing for efficacy.

For further insights into TSE:MDNA stock, check out TipRanks’ Stock Analysis page.